Korro Bio Inc 's

Name: Korro Bio Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

KRRO Sales vs. its Competitors Q2 2026

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

<< KRRO Stock Performance Comparisons

<< See the full list of KRRO competitors

*Market share is calculated based on total revenue.

News about Korro Bio Inc Contracts

Korro Bio Announces Key Regulatory Milestone and Financial Performance Amidst Strategic Development Initiatives

November 4, 2024
: Korro Bio, Inc. (Nasdaq: KRRO), a biopharmaceutical company dedicated to the advancement of innovative genetic medicines for a range of rare and common diseases, has recently marked significant milestones in its strategic roadmap. The company has announced the submission of a regulatory filing for a Phase 1/2 clinical study of KRRO-110, targeting Alpha-1 Antitrypsin Deficiency (AATD), to the Bellberry Human Research Ethics Committee (HREC) in Australia. Concurrently, Korro reported its full year 2023 financial results, highlighting strategic achievements and setting the stage for future advancements. This article synthesizes these developments, emphasizing Korro Bio’s commitment to pioneering medical res...

Korro Bio's Genetic Breakthrough Promises Hope for Rare Disease Patients and Expands Potential for Future Cures

January 18, 2024
Korro Bio Presents Promising Data for its Genetic Medicines in Alpha-1 Antitrypsin Deficiency and Advances in RNA Editing PortfolioKorro Bio, a leading biopharmaceutical company based in Cambridge, Massachusetts, made a significant impact at the recent J.P. Morgan Healthcare Conference on January 9, 2024. The company presented compelling new data for its lead program, KRRO-110, targeting Alpha-1 Antitrypsin Deficiency (AATD), and highlighted progress across its RNA editing portfolio.KRRO-110 is part of Korro Bio s pioneering approach to developing a new class of genetic medicines for rare and highly prevalent diseases. AATD, a genetic disorder that affects the lungs and liver, can cause serious damage, incl...

KRRO's Stock Performance relative to its Competitors

Publicly Traded Peers of Korro Bio Inc

Sources: Korro Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Korro Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.